Home > Formulary : Paediatric > Paediatric Chapters > 2. Cardiovascular system >
BNSSG Paediatric Joint Formulary
2.2 Bleeding disorders
Last edited: 02-07-2025
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
2.2 Bleeding disorders
Secondary Care to maintain responsibility for monitoring amber specialist initiated drugs in the cardiovascular section of the Paediatric formulary. A clear management plan detailed in the clinic letter is required to support primary care prescribing. GP Practices should ensure a plan is in place before taking over prescribing responsibility
Antifibrinolytic Drugs and Haemostatics
Tranexamic Acid (TLS Green)
2.2 Subarachnoid haemorrhage
Nimodipine (TLS Red)
2.3 Haemophilia
Haemophilia A
Efanesoctocog alfa (TLS Red)
- NICE TA1051 Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over
Haemophilia B
Marstacimab (TLS Red)
- NHSE SSC 2836 Marstacimab for treating severe haemophilia B in people 12 years and over without anti-factor antibodies